Whalesbook: AI-Powered Stock Updates via WhatsApp

Stock Analysis

Description

Incorporated in 1995, Nectar Lifesciences Ltd manufactures APIs and Formulations.

Key Growth Triggers

Significant debt reduction through asset sales and repayments.
Focus on optimizing capital structure and enhancing shareholder value via buyback.
Strategic pivot following divestment of API, formulations, and menthol businesses.
Potential reinvestment in new projects and high-growth sectors.

Order Book

Currently no data available for Order Book.

Key Red Flags

Reported net losses in recent quarters, primarily from discontinued operations.
Historical challenges with sales growth and profitability prior to restructuring.

Key Dates To Watch

Completion of ₹81 crore equity share buyback by January 13, 2026.
Disclosure of Q3 FY26 financial results, with trading window closure until 48 hours post-announcement.

Corporate Announcements

8th Apr 26

Impact Rating: 5

Nectar Lifesciences has started its second 100-day "Saksham Niveshak" outreach campaign from April 1, 2026, to July 9, 2026, to help investors update KYC and claim any unpaid dividends.

6th Apr 26

Impact Rating: 4

Nectar Lifesciences Ltd. has submitted a SEBI Regulation 74(5) certificate for the quarter ended March 31, 2026, confirming proper handling of dematerialization requests and listing of securities as per norms.

25th Mar 26

Impact Rating: 4

Nectar Lifesciences Limited will close its trading window for designated persons and their immediate relatives from April 1, 2026. The closure lasts until 48 hours after the announcement of financial results for the period ending March 31, 2026.

13th Mar 26

Impact Rating: 7

Nectar Lifesciences Ltd. shareholders approved key resolutions, including appointing Mr. Sushil Kapoor as Director and Wholetime Director (Finance) with a ₹3.00 lakh (₹0.03 cr) monthly salary, and amending the MOA.

12th Mar 26

Impact Rating: 9

Nectar Lifesciences has signed an inter-corporate loan agreement with its subsidiary AEPL for an amount not exceeding ₹100 crore, with a fixed tenure of 10 years.

Peer Comparision

S.No.	Name	Current Price (Rs.)	Price to Earning	Market Capitalization (Rs.Cr.)	Dividend yield (%)	Net Profit latest quarter (Rs.Cr.)	YOY Quarterly profit growth (%)	Sales latest quarter (Rs.Cr.)	YOY Quarterly sales growth (%)	Return on capital employed (%)	Sales (Rs.Cr.)	OPM (%)	Profit after tax (Rs.Cr.)	Profit after tax latest quarter (Rs.Cr.)	Price to book value	Return on assets (%)	Debt to equity
1.	Sun Pharma.Inds.	1782.60	37.05	427717.60	0.90	3124.95	2.56	14478.31	8.93	20.21	54964.01	30.12	11543.96	3117.95	5.50	12.97	0.07
2.	Divi's Lab.	6642.50	70.94	176292.38	0.45	689.00	35.10	2715.00	16.12	20.44	10029.00	32.37	2485.00	689.00	11.44	13.53	0.01
3.	Torrent Pharma.	4092.20	63.93	138496.88	0.78	591.00	32.49	3302.00	14.30	27.05	12248.00	32.60	2166.53	600.17	16.39	13.26	0.33
4.	Cipla	1467.90	21.80	118607.61	0.89	1353.37	3.73	7589.44	7.64	22.72	28349.57	25.40	5441.14	1351.17	3.60	14.72	0.01
5.	Dr Reddy's Labs	1242.80	17.97	103748.51	0.64	1336.80	7.28	8828.30	9.83	22.69	34310.00	24.64	5772.20	1347.10	2.88	12.95	0.16
6.	Lupin	2214.30	23.36	101043.20	0.54	1484.83	73.34	7047.51	24.23	21.30	24750.69	27.25	4324.63	1477.92	5.15	12.41	0.32
7.	Mankind Pharma	2311.80	54.55	95387.58	0.04	520.18	-22.00	3697.16	20.77	15.98	13545.67	24.12	1748.55	511.51	6.24	8.89	0.55
8.	Nectar Lifesci.	18.97	–	426.96	0.00	-176.01	-43.48	5.71	-0.52	-5.36	896.63	-12.35	-123.26	-0.33	0.59	-5.37	0.64
–	Median: 150 Co.	409.67	30.81	1757.37	0.11	13.03	12.32	157.2	10.84	14.98	582.87	15.96	44.55	13.73	3.15	8.6	0.22

Quarterly Results

Standalone figures in ₹ crores

	Dec 2022	Dec 2023	Dec 2024	Jun 2023	Jun 2024	Jun 2025	Mar 2023	Mar 2024	Mar 2025	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Sales	344	452	455	394	359	5	389	441	431	389	398	6	6
Expenses	343	410	410	359	319	6	369	393	585	396	371	6	6
Operating Profit	1	42	45	36	40	-1	20	49	-154	-7	27	-1	-0
Other Income	13	0	1	0	1	-62	18	1	0	11	11	7	-176
Profit before tax	-18	2	13	3	5	-64	3	11	-188	-32	2	5	-176
Tax %	-47%	36%	38%	41%	40%	-1%	-68%	95%	-31%	-31%	38%	-2%	-0%
Net Profit	-9	2	8	2	3	-63	5	1	-130	-22	1	6	-176
EPS in Rs	-0.41	0.07	0.35	0.08	0.13	-2.82	0.24	0.03	-5.80	-1.00	0.05	0.25	-7.85

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	1,634	1,638	1,675	1,635	1,873	2,781	2,360	1,539	1,664	1,522	1,682	1,664	897
Expenses	1,345	1,371	1,436	1,411	1,637	2,517	2,142	1,430	1,506	1,467	1,530	1,694	1,007
Operating Profit	289	267	239	224	236	264	218	109	159	55	152	-30	-111
Other Income	12	20	6	23	6	6	4	-22	11	43	15	5	-237
Interest	138	126	123	117	115	148	126	112	79	79	87	75	35
Depreciation	84	77	57	62	64	63	61	60	57	59	61	62	32
Profit before tax	78	85	64	67	63	59	36	-85	34	-41	18	-162	-415
Net Profit	62	66	54	55	52	47	30	-73	25	-22	5	-114	-361
EPS in Rs	2.77	2.95	2.42	2.46	2.33	2.11	1.34	-3.26	1.13	-1.00	0.22	-5.07	-16.12
Dividend Payout %	4%	3%	4%	2%	2%	2%	4%	0%	0%	0%	0%	0%	–

Balance Sheet

Standalone figures in ₹ crores

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sep 2025
Equity Capital	22	22	22	22	22	22	22	22	22	22	22	22	22
Reserves	905	936	932	984	1,036	1,082	1,112	1,038	1,064	1,042	1,047	934	694
Borrowings	858	925	962	878	955	903	779	903	860	754	636	582	459
Other Liabilities	609	628	640	696	710	696	719	423	443	371	486	509	639
Total Liabilities	2,394	2,510	2,557	2,581	2,724	2,704	2,632	2,387	2,390	2,189	2,191	2,047	1,815
Fixed Assets	948	934	906	881	852	825	785	772	723	662	643	633	28
Gross Block	1,341.15	1,451.42	1,383.66	1,420.94	1,456.36	1,490.50	1,508.81	1,555.70	1,562.95	1,557.96	1,599.41	1,652.17	–
Accumulated Depreciation	393.61	517.69	478.08	539.70	604.00	665.68	723.96	783.81	839.85	895.99	956.71	1,019.06	–
CWIP	122	91	99	102	100	100	115	99	85	78	66	57	0
Investments	0	1	1	1	1	1	1	1	1	1	1	1	1
Other Assets	1,324	1,485	1,551	1,597	1,771	1,778	1,732	1,515	1,580	1,449	1,482	1,357	1,786
Total Assets	2,394	2,510	2,557	2,581	2,724	2,704	2,632	2,387	2,390	2,189	2,191	2,047	1,815

Cash Flows

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	255	144	169	199	65	239	286	21	95	133	225	169
Cash from Investing Activity	-90	-60	-77	-18	-29	-26	-33	-29	17	52	-17	-42
Cash from Financing Activity	-161	-61	-89	-204	-40	-201	-252	11	-119	-186	-205	-128
Net Cash Flow	4	23	3	-24	-4	12	1	4	-8	-0	2	-1

Ratios

Standalone Figures in ₹ Crores / Yearly

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	84	99	107	112	119	74	61	89	98	67	82	76
Inventory Days	240	253	260	270	226	150	192	185	197	212	215	184
Days Payable	139	146	154	167	142	79	104	108	112	100	127	117
Cash Conversion Cycle	185	207	213	215	203	145	149	166	183	178	170	143
Working Capital Days	23	40	41	46	67	46	53	6	73	77	63	43
ROCE %	12%	11%	10%	10%	9%	10%	8%	3%	5%	-0%	6%	-5%

Shareholding Pattern

Numbers in percentages

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	55.80%	44.53%	44.53%	44.53%	44.91%	44.91%
FIIs	15.99%	16.07%	16.00%	16.02%	16.12%	16.98%	16.60%	3.24%	0.73%	1.65%	0.82%	0.62%	0.52%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.15%	0.19%	0.08%	5.82%
Public	28.20%	28.12%	28.18%	28.17%	28.05%	27.20%	27.57%	40.94%	54.72%	53.64%	54.45%	54.37%	48.73%